Indeed, the inhibition of tumor progression caused by inhibitors against NF‐κB signals has been shown in colon, lung, and breast cancers, whereas it is still unclear how the activity of NF‐κB is regulated by oncogenic signals (Fernandez‐Majada et al., 2007; Rahman et al., 2007). The gene discussed is NFKB1; the disease is breast carcinoma.